(S)-2-Amino-3-((3R,4S,5S,6R)-3,4,5-trihydroxy-6-hydroxymethyl-tetrahydro-pyran-2-yloxy)-propionic acid | 32257-92-4

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (S)-2-Amino-3-((3R,4S,5S,6R)-3,4,5-trihydroxy-6-hydroxymethyl-tetrahydro-pyran-2-yloxy)-propionic acid
• 英文别名: (2S)-2-amino-3-[(3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropanoic acid
• CAS: 32257-92-4
• 化学式: C₉H₁₇NO₈
• 分子量: 267.236
• InChiKey: HGTOXWOVJAONKK-PIRQICBKSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -5.6
• 重原子数：
  18
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.89
• 拓扑面积：
  163
• 氢给体数：
  6
• 氢受体数：
  9

文献信息

• Glycosylated PACAP/VIP analogues with enhanced CNS penetration for treatment of neurodegenerative diseases
  申请人：THE ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA

  公开号：US10117907B2

  公开（公告）日：2018-11-06

  A glycosylated pleiotropic peptide pituitary adenylate cyclase-activating polypeptide (PACAP) which can both agonize PAC1 receptors, causing neuroprotective effects, and antagonize VPAC receptors, causing anti-inflammation in several models of acute neuronal damage and neurodegenerative diseases, including ALS, PD, migraines, and certain forms of dementia, is described. Also described is a method of relieving symptoms of ALS, PD, migraines, and certain forms of dementia, comprising administering to a subject in need thereof an effective amount of a glycosylated PACAP.

  本文描述了一种糖基化多肽垂体腺苷酸环化酶激活多肽（PACAP），它既能激动 PAC1 受体，从而产生神经保护作用，又能拮抗 VPAC 受体，从而在急性神经元损伤和神经退行性疾病（包括渐冻人症、帕金森病、偏头痛和某些形式的痴呆症）的几种模型中产生抗炎作用。还描述了一种缓解 ALS、PD、偏头痛和某些形式痴呆症症状的方法，包括向有需要的受试者施用有效量的糖基化 PACAP。
• Glycosylated peptides with pseudoproline residues and having enhanced half-lives and ability to cross the blood brain barrier
  申请人：ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA

  公开号：US10858410B2

  公开（公告）日：2020-12-08

  Glycosylated peptides with glycosylation at or near the C-terminal domain of the peptide have an enhanced ability to cross the blood brain barrier (BBB) and/or enhanced half-lives. These glycosylated peptides may be used as drugs. For example, a PACAP peptide with a C-terminal glycosylation, e.g., in lieu of the terminal leucine, functions as a PAC1 agonist with enhanced ability to cross the BBB and with enhanced half-life. The peptides can have a pseudoproline residue with glycosylation at or near the C-terminal domain.

  在肽的 C 端或 C 端附近糖基化的糖基化肽具有更强的穿越血脑屏障（BBB）的能力和/或更长的半衰期。这些糖基化多肽可用作药物。例如，具有 C-末端糖基化的 PACAP 肽（如代替末端亮氨酸）可作为 PAC1 激动剂，具有更强的穿过 BBB 的能力和更长的半衰期。这种多肽可以在 C 端结构域或其附近具有糖基化的假脯氨酸残基。
• AMPHIPATHIC GLYCOPEPTIDES
  申请人：Polt, Robin

  公开号：EP1729790A1

  公开（公告）日：2006-12-13
• TREATMENT OF TRAUMATIC BRAIN INJURY OR STROKE
  申请人：The Arizona Board of Regents On Behalf of the University of Arizona

  公开号：EP3416977A1

  公开（公告）日：2018-12-26
• Amphipathic Glycopeptides
  申请人：Polt Robin

  公开号：US20080207492A1

  公开（公告）日：2008-08-28

  Glycopeptides which are amphipathic and capable of crossing the blood-brain-barrier are provided. The glycopeptides are useful for treating a variety of neurological an behavioral disorders.